VANCOUVER, Oct. 27 /PRNewswire/ - iCo Therapeutics Inc. announced today
that Dr. David S. Boyer will join its strategic advisory team. As an
ophthalmologist and senior partner of the Retina-Vitreous Associates
Medical Group in California, Dr. Boyer specializes in diseases of the
retina and vitreous. He is a Clinical Associate Professor of Ophthalmology
at the University of Southern California and has worked on trials for
age-related macular degeneration, diabetic retinopathy, and cytomegalovirus
"We are pleased to have Dr. Boyer join our advisory team," said Andrew
Rae, iCoTherapeutics' President and Chief Executive Officer. "His clinical
knowledge and experience as an advisor to dynamic and successful
biotechnology companies brings strength to our strategic advisory team."
Dr. Boyer has served on the advisory boards for Alcon, Novartis,
Eyetech/Pfizer, Genentech, Neurotech and the Macular Degeneration
Partnership. He is a reviewer for several ophthalmology and diabetes
medical publications including Archives of Ophthalmology, American Journal
of Ophthalmology, Diabetes Care, and Ophthalmology.
Throughout his career, Dr. Boyer has been honoured by prestigious
organizations including the American Academy of Ophthalmology (Board of
Trustees Honor Award Certificate) and Retinitis Pigmentosa International
(1996 Jules Stein Living Tribute Award). Every year since 2000, he has been
selected by his peers to be listed in Best Doctors In America.
Dr. Boyer's professional affiliations include the Los Angeles Medical
Association, Los Angeles Eye Society, American Board of Ophthalmology,
Discovery Fund for Eye Research, American Academy of Ophthalmology and
Otolaryngology, California Medical Association, Vitreous Society, American
Medical Association, Retinitis Pigmentosa International, and the American
Diabetes Association. Dr. Boyer earned his medical degree at Chicago
Medical School, completed his internship and residency at the USC/Los
Angeles County Medical Center, and went on to do his fellowship in retinal
surgery at the Wills Eye Hospital in Philadelphia.
iCo Therapeutics Inc. is an emerging, Vancouver-based biotechnology
company focused on developing pre-existing drugs for a range of new
conditions affecting isolated biological environments - areas such as the
eye, spinal cord, or joints - where locally-administered application of
these therapies would have minimal systemic distribution and fewer safety
For more information, visit the company website at:
CONTACT: Business Development Contact: Dr. John Clement, CT&DO, (778)
688-0644; Finance/Investor Contact: Mr. John Meekison, CFO, (604) 602-9414;
Media Contact: Amanda Smith, Principal, Smith Biotech, (778) 846-4116
SOURCE iCo Therapeutics Inc.